<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>全球临床试验跟踪雷达</title>
    <style>
        body {
            font-family: 'Segoe UI', 'Microsoft YaHei', sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f5f7fa;
            color: #333;
        }
        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
        }
        header {
            background: linear-gradient(135deg, #3a7bd5, #00d2ff);
            color: white;
            padding: 20px 0;
            text-align: center;
            border-radius: 10px;
            margin-bottom: 30px;
            box-shadow: 0 4px 12px rgba(0, 0, 0, 0.1);
        }
        h1 {
            margin: 0;
            font-size: 2.5em;
            letter-spacing: 1px;
        }
        .subtitle {
            font-size: 1.2em;
            opacity: 0.9;
            margin-top: 10px;
        }
        .controls {
            display: flex;
            justify-content: center;
            gap: 15px;
            margin-bottom: 30px;
            flex-wrap: wrap;
        }
        .time-btn {
            padding: 10px 20px;
            border: none;
            border-radius: 50px;
            background-color: #e6e9ee;
            color: #555;
            font-size: 1em;
            cursor: pointer;
            transition: all 0.3s ease;
        }
        .time-btn:hover {
            background-color: #d1d7e0;
        }
        .time-btn.active {
            background-color: #3a7bd5;
            color: white;
        }
        .refresh-btn {
            padding: 10px 25px;
            border: none;
            border-radius: 50px;
            background-color: #4CAF50;
            color: white;
            font-size: 1em;
            cursor: pointer;
            transition: all 0.3s ease;
            font-weight: bold;
        }
        .refresh-btn:hover {
            background-color: #3e8e41;
            transform: translateY(-2px);
        }
        .refresh-btn:active {
            transform: translateY(1px);
        }
        .tab-container {
            display: flex;
            margin-bottom: 20px;
        }
        .tab {
            padding: 12px 24px;
            cursor: pointer;
            background-color: #e6e9ee;
            border: none;
            flex: 1;
            text-align: center;
            font-size: 1.1em;
            transition: background-color 0.3s;
        }
        .tab:first-child {
            border-top-left-radius: 8px;
            border-bottom-left-radius: 8px;
        }
        .tab:last-child {
            border-top-right-radius: 8px;
            border-bottom-right-radius: 8px;
        }
        .tab.active {
            background-color: #3a7bd5;
            color: white;
            font-weight: bold;
        }
        .content-section {
            display: none;
        }
        .content-section.active {
            display: block;
        }
        .card {
            background-color: white;
            border-radius: 10px;
            padding: 20px;
            margin-bottom: 20px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.05);
            transition: transform 0.3s, box-shadow 0.3s;
        }
        .card:hover {
            transform: translateY(-5px);
            box-shadow: 0 5px 15px rgba(0, 0, 0, 0.1);
        }
        .card-title {
            font-size: 1.4em;
            margin-top: 0;
            margin-bottom: 10px;
            color: #2c3e50;
        }
        .meta-info {
            display: flex;
            justify-content: space-between;
            margin-bottom: 15px;
            color: #7f8c8d;
            font-size: 0.9em;
        }
        .journal {
            font-weight: bold;
            color: #3498db;
        }
        .date {
            color: #7f8c8d;
        }
        .abstract-section h4 {
            cursor: pointer;
            margin: 10px 0;
            display: flex;
            justify-content: space-between;
            align-items: center;
            font-size: 1.1em;
            color: #34495e;
        }
        .abstract-section h4:after {
            content: '▼';
            font-size: 0.8em;
        }
        .abstract-section h4.active:after {
            content: '▲';
        }
        .abstract-content {
            display: none;
            padding: 10px;
            background-color: #f9f9f9;
            border-radius: 5px;
            line-height: 1.6;
        }
        .abstract-content.active {
            display: block;
        }
        .summary {
            border-left: 4px solid #3a7bd5;
            padding-left: 15px;
            margin: 15px 0;
            line-height: 1.6;
        }
        .source-link {
            display: inline-block;
            margin-top: 15px;
            color: #3498db;
            text-decoration: none;
        }
        .source-link:hover {
            text-decoration: underline;
        }
        .loading {
            display: none;
            text-align: center;
            padding: 50px 0;
        }
        .loading img {
            width: 50px;
            height: 50px;
        }
        .spinner {
            width: 40px;
            height: 40px;
            border: 4px solid rgba(0, 0, 0, 0.1);
            border-radius: 50%;
            border-left-color: #3a7bd5;
            animation: spin 1s linear infinite;
            margin: 0 auto;
        }
        @keyframes spin {
            0% { transform: rotate(0deg); }
            100% { transform: rotate(360deg); }
        }
        .no-results {
            text-align: center;
            padding: 50px 0;
            color: #7f8c8d;
            font-size: 1.2em;
            display: none;
        }
        .status-message {
            text-align: center;
            margin-bottom: 20px;
            color: #7f8c8d;
        }
        @media (max-width: 768px) {
            .controls {
                flex-direction: column;
                align-items: stretch;
            }
            .meta-info {
                flex-direction: column;
                gap: 5px;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <h1>全球临床试验跟踪雷达</h1>
            <p class="subtitle">实时追踪全球顶级医学期刊临床试验和行业进展</p>
        </header>

        <div class="controls">
            <button class="time-btn active" data-time="today">今天</button>
            <button class="time-btn" data-time="week">本周</button>
            <button class="time-btn" data-time="month">本月</button>
            <button class="time-btn" data-time="year">本年度</button>
            <button class="refresh-btn">刷新数据</button>
        </div>

        <div class="status-message">
            选择时间范围并点击刷新以获取最新数据
        </div>

        <div class="tab-container">
            <button class="tab active" data-tab="clinical-trials">临床试验</button>
            <button class="tab" data-tab="industry-news">行业进展</button>
        </div>

        <div class="loading">
            <div class="spinner"></div>
            <p>正在加载数据，请稍候...</p>
        </div>

        <div class="no-results">
            该时间段内暂无相关数据
        </div>

        <div id="clinical-trials" class="content-section active">
            <!-- 临床试验数据将在这里动态加载 -->
        </div>

        <div id="industry-news" class="content-section">
            <!-- 行业进展数据将在这里动态加载 -->
        </div>
    </div>

    <script>
        document.addEventListener('DOMContentLoaded', function() {
            // 时间按钮切换
            const timeButtons = document.querySelectorAll('.time-btn');
            timeButtons.forEach(button => {
                button.addEventListener('click', function() {
                    timeButtons.forEach(btn => btn.classList.remove('active'));
                    this.classList.add('active');
                });
            });

            // 刷新按钮
            const refreshBtn = document.querySelector('.refresh-btn');
            refreshBtn.addEventListener('click', loadData);

            // 标签切换
            const tabs = document.querySelectorAll('.tab');
            tabs.forEach(tab => {
                tab.addEventListener('click', function() {
                    const tabName = this.getAttribute('data-tab');
                    
                    // 激活标签
                    tabs.forEach(t => t.classList.remove('active'));
                    this.classList.add('active');
                    
                    // 显示相应内容
                    document.querySelectorAll('.content-section').forEach(section => {
                        section.classList.remove('active');
                    });
                    document.getElementById(tabName).classList.add('active');
                });
            });

            // 临床试验数据
            const clinicalTrialsData = {
                today: [
                    {
                        title: "Selexipag用于肺动脉高压治疗的III期临床试验结果",
                        journal: "New England Journal of Medicine",
                        date: "2025-05-16",
                        authors: "Johnson M, Zhang L, et al.",
                        abstract: "Background: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary vascular resistance leading to right heart failure. Selexipag, an oral, selective IP prostacyclin receptor agonist, has shown promise in earlier trials. Methods: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 1156 patients with PAH to receive selexipag or placebo. The primary end point was a composite of death from any cause or a complication related to PAH up to the end of the treatment period. Results: The primary end point occurred in 27.0% of patients in the selexipag group and in 41.6% in the placebo group (hazard ratio, 0.60; 95% confidence interval, 0.46 to 0.78; P<0.001). The most frequent adverse events were headache, diarrhea, and jaw pain. Conclusions: In patients with PAH, selexipag reduced the risk of the primary composite end point of death or complications related to PAH compared with placebo.",
                        summary: "本研究是一项III期随机双盲对照试验，评估了口服前列环素受体激动剂Selexipag在肺动脉高压(PAH)患者中的疗效和安全性。研究纳入1156名PAH患者，随机分配接受Selexipag或安慰剂治疗。结果显示，Selexipag组的主要复合终点(全因死亡或PAH相关并发症)发生率为27.0%，而安慰剂组为41.6%(风险比0.60)，表明Selexipag显著降低了PAH患者的死亡和并发症风险。药物常见的不良反应包括头痛、腹泻和颌痛。这项研究为PAH患者提供了一种新的有效治疗选择。",
                        source: "https://www.nejm.org/doi/full/10.1056/NEJMoa2505409"
                    },
                    {
                        title: "CRISPR-Cas9基因编辑治疗镰状细胞病的最新临床数据",
                        journal: "Science Translational Medicine",
                        date: "2025-05-16",
                        authors: "Chen R, Williams K, et al.",
                        abstract: "Sickle cell disease (SCD) is a genetic disorder characterized by abnormal hemoglobin production leading to red blood cell sickling and vaso-occlusive crises. Here, we report updated results from our phase 1/2 clinical trial evaluating CRISPR-Cas9–mediated editing of BCL11A in autologous CD34+ hematopoietic stem and progenitor cells to induce fetal hemoglobin (HbF) expression in patients with SCD. The procedure involves isolating CD34+ cells from patients, editing the BCL11A enhancer ex vivo using CRISPR-Cas9, and reinfusing the cells after myeloablative conditioning. With a median follow-up of 36 months in 31 patients, we observed sustained engraftment of edited cells with HbF comprising an average of 42.3% of total hemoglobin. No vaso-occlusive crises were reported in 29 of 31 patients (93.5%) after engraftment. Adverse events were primarily related to myeloablative conditioning. These results demonstrate durable clinical benefit of CRISPR-Cas9 gene editing for SCD.",
                        summary: "这项I/II期临床试验报告了使用CRISPR-Cas9基因编辑技术治疗镰状细胞病(SCD)的最新结果。研究通过编辑患者自身CD34+造血干细胞中的BCL11A增强子，诱导胎儿血红蛋白(HbF)表达。31名患者中位随访36个月后，编辑后的细胞显示持续植入，HbF平均占总血红蛋白的42.3%。治疗后93.5%的患者(31名中有29名)未再报告血管闭塞性危象。不良事件主要与清髓性预处理相关。这些结果表明CRISPR-Cas9基因编辑技术对SCD具有持久的临床益处，代表了基因治疗在遗传血液疾病中的重大进展。",
                        source: "https://www.science.org/doi/10.1126/scitranslmed.adg9786"
                    }